Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States.

CHART-1 is a patient prospective, controlled multi-centre, randomized, double-blinded phase III clinical trial comparing treatment with C-Cure to a sham treatment. Cardio3 BioSciences’ C-Cure therapy involves taking stem cells from a patient’s own bone marrow and through a proprietary process called Cardiopoiesis, re-programming those cells to become heart cells. The cells, known as cardiopoietic cells, are then injected back into the patient’s heart through a minimally invasive procedure, with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The company’s proprietary HypoThermosol and CryoStor biopreservation media products are highly valued in the biobanking, drug discovery, and regenerative medicine markets.

ADVERTISEMENT

BioLife CEO Mike Rice

Mike Rice

Mike Rice, BioLife Solutions CEO, remarked; “We are honored to be able to supply our clinical grade CryoStor cell freeze media for Cardio3 Biosciences’ phase III clinical trials. Congestive heart failure is a leading cause of death and C-Cure is a novel and potentially life-saving, cell-based therapy that offers hope to millions of patients throughout the world.  We are very well positioned to participate in the growth of the regenerative medicine market, with our products being used in at least 75 phase II and over 20 phase III clinical trials of new cell and tissue based products and therapies.”

Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD. 

Previous post

FuturaGene's Genetically Modified Eucalyptus approved in Brazil

Next post

Injaz, the world’s first cloned camel, is pregnant

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.